In previous studies, the genetic variants of SLCO1B1 were proven to be relevant to the response to drugs transported by OATP1B1, such as statin-induced myopathy, irinotecan-induced toxicities, methotrexate clearance (Carr et al., 2013; Link et al., 2008; Hussain et al., 2023). Here, SLCO1B1 is linked to myopathy.